Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer.

Zeliadt SB, Potosky AL, Penson DF, Etzioni R
Int J Radiat Oncol Biol Phys. 2006 66 (2): 395-402

PMID: 16904843 · DOI:10.1016/j.ijrobp.2006.04.048

BACKGROUND - The use of adjuvant androgen deprivation therapy (ADT) combined with radiotherapy has become common in low-risk patients, although clinical trials have focused primarily on high-risk patients. This study examines the effectiveness of adjuvant ADT combined with radiotherapy for a wide range of patients treated in the 1990s.

METHODS AND MATERIALS - Prostate cancer survival was examined in a population based cohort of 31,643 patients aged 65 to 85 years who were diagnosed with nonmetastatic prostate cancer and treated with external beam radiotherapy and/or brachytherapy. Instrumental variable analysis methods were used to control for selection bias.

RESULTS - Patients with stage T3/T4 disease who received adjuvant ADT experienced improved 5-year and 8-year survival. No survival advantage was observed for men with T1/T2 disease during this interval.

CONCLUSION - High-risk patients who receive primary radiotherapy have benefited from adjuvant ADT, whereas low-risk patients with disease confined to the prostate have not yet benefited from adjuvant therapy within the first 8 years after treatment. These findings are consistent with practice guidelines, which recommend adjuvant ADT for patients with high-risk disease.

MeSH Terms (12)

Aged Aged, 80 and over Androgen Antagonists Chemotherapy, Adjuvant Humans Male Neoplasm Staging Proportional Hazards Models Prostatic Neoplasms SEER Program Socioeconomic Factors Survival Analysis

Connections (1)

This publication is referenced by other Labnodes entities:

Links